Thus, regarding potential explanations for the biological effects of synergy between SMAD2 and TGFBR2, we speculate that the SMAD2 and TGFBR2 gene products may participate in a common pathogenic pathway, that is the TGF-β signaling pathway, leading to MetS. Here, TGFBR2 is linked to metabolic syndrome.